Global Hemangiomas Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Hemangiomas Treatment Market Analysis

The hemangiomas treatment market has been witnessing significant growth, driven by advancements in medical treatments and an increasing prevalence of hemangiomas, especially in infants. Hemangiomas are benign vascular tumors that typically form on the skin or internal organs. They are commonly treated through medications, laser therapy, and, in severe cases, surgery. The market is expanding with the development of innovative treatments such as beta-blockers, corticosteroids, and new laser technologies, providing more effective, minimally invasive options for patients. In recent developments, the approval of new drugs and therapeutic techniques has bolstered treatment options, improving patient outcomes. In addition, the growing awareness about hemangiomas and advancements in diagnostic tools, such as CT scans and angiograms, have contributed to early detection and timely interventions. This has increased the demand for specialized treatments, especially in pediatric care, and spurred growth in the hemangiomas treatment market globally.

Hemangiomas Treatment Market Size

The global hemangiomas treatment market size was valued at USD 1.86 billion in 2024 and is projected to reach USD 2.49 billion by 2032, with a CAGR of 3.70% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hemangiomas Treatment Market Trends

“Advancements in Medical Technologies”

The hemangiomas treatment market is experiencing notable growth, driven by increasing awareness and advancements in medical technologies. Innovations in non-invasive treatments, such as laser therapies and oral medications such as beta-blockers, have revolutionized the management of hemangiomas, offering effective alternatives to surgery. One key trend in the market is the growing preference for minimally invasive treatments, which are safer and require less recovery time, especially for pediatric patients. Laser treatments, in particular, are gaining popularity due to their precision and reduced side effects. As research into hemangioma treatments continues, the market is expected to expand with new therapeutic options, enhanced efficacy, and improved patient outcomes, solidifying the trend toward non-surgical interventions.

Report Scope and Hemangiomas Treatment Market Segmentation   

Hemangiomas Treatment Market Definition

Hemangiomas treatment refers to the medical interventions used to manage and reduce the size of hemangiomas, which are benign tumors formed by an abnormal growth of blood vessels. These treatments aim to alleviate symptoms, prevent complications, and in some cases, promote the regression of the hemangioma. Common treatment options include oral medications (such as beta-blockers), laser therapies, surgical procedures, and corticosteroids. The choice of treatment depends on the size, location, and severity of the hemangioma, as well as the age and health of the patient.

Hemangiomas Treatment Market Dynamics

Drivers

• Rising Incidence of Hemangiomas

The growing number of diagnosed hemangioma cases, particularly in infants, is a key driver for the hemangiomas treatment market. Hemangiomas, often appearing shortly after birth, are increasingly being detected due to improved diagnostic tools and greater awareness among healthcare professionals and parents. As these cases rise, there is a higher demand for effective treatments, ranging from oral medications such as beta-blockers to advanced surgical and laser options. The need for targeted therapies that can manage both superficial and deep hemangiomas effectively is growing, driving the development of new treatments and contributing to the market’s expansion.

• Expansion of Pediatric Healthcare

As pediatric healthcare continues to improve worldwide, there is an increased focus on treating hemangiomas in children, fueling the growth of the hemangiomas treatment market in pediatric segments. Advancements in pediatric healthcare, such as better access to medical care, earlier diagnoses, and improved treatment options, have made it easier to manage conditions such as hemangiomas effectively. With a greater emphasis on ensuring healthy child development, parents and healthcare providers are more proactive in seeking treatments that can prevent complications related to hemangiomas. This growing focus on pediatric care is a significant driver of demand for specialized hemangioma therapies tailored to children’s needs.

Opportunities

• Non-Invasive Treatment Demand

The growing preference for non-invasive treatment options, particularly laser therapy, presents a significant market opportunity in the hemangioma treatment sector. Laser treatments are highly favored due to their ability to target hemangiomas with precision, minimizing damage to surrounding tissue. This results in improved cosmetic outcomes and reduced recovery times, which are key considerations for both patients and healthcare providers. As patients increasingly seek less invasive alternatives to traditional surgeries, the demand for laser-based therapies is expected to rise. This shift toward non-invasive treatments creates opportunities for innovation, market expansion, and investment in developing advanced, effective, and accessible therapies.

• Telemedicine for Diagnosis and Monitoring

With the increasing adoption of telemedicine, there is a significant market opportunity to integrate remote consultations for the diagnosis, treatment planning, and ongoing monitoring of hemangiomas. Telemedicine allows healthcare professionals to conduct virtual assessments, reducing the need for in-person visits, which is especially beneficial for patients in remote or underserved areas. This can enhance early diagnosis and timely interventions, improving treatment outcomes. Moreover, telehealth enables continuous follow-up care, providing patients with greater convenience and reducing travel times and associated costs. As healthcare systems evolve, telemedicine can play a pivotal role in expanding access to specialized hemangioma treatments and improving overall patient satisfaction.

Restraints/Challenges

• Limited Treatment Options for Complicated Cases

Despite the availability of treatment options such as laser therapy, oral medications, and surgery, one of the key challenges in the hemangioma treatment market is the lack of effective therapies for complicated or severe cases. Hemangiomas that affect internal organs or deeper tissues are particularly difficult to treat, as they may require more specialized approaches. Current treatments may not be universally effective for all types or locations of hemangiomas, limiting their application. This gap in available treatments for more complex cases restricts market growth and creates a need for ongoing research and development to address these specific challenges in hemangioma care.

•  High Cost of Advanced Therapies

One of the significant restraints in the hemangioma treatment market is the high cost of advanced therapies, such as laser treatments and surgery. These procedures, while effective, can be prohibitively expensive, especially in regions where healthcare insurance coverage is limited or unavailable. For lower-income patients or those without adequate health insurance, the financial burden may prevent access to necessary treatments, creating a barrier to care. This economic constraint limits the reach of the market, as a substantial portion of the population may not afford these treatments. Addressing these financial barriers is crucial for expanding access and ensuring wider adoption of hemangioma therapies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hemangiomas Treatment Market Scope

The market is segmented on the basis of drug class, type, diagnosis, treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Beta blocker Medication
• Anti-inflammatory Medication
• Others

Type

• External Hemangioma
• Internal Hemangioma

Diagnosis

• X Ray
• Computerized Tomography (CT) Scans
• Biopsy
• Angiogram
• Others

Treatment Type

• Medication
• Surgery
• Laser Treatment
• Others

Route of Administration

• Oral
• Injectable
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Hemangiomas Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug class, type, diagnosis, treatment type, route of administration, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hemangioma treatment market, driven by a rising incidence of infantile hemangiomas and an increasing number of adult hemangioma cases in the region. The region's advanced healthcare infrastructure and access to specialized treatments contribute to its dominance. In addition, growing awareness and early diagnosis further boost demand for effective therapies in North America.

Europe is projected to experience significant growth in the hemangioma treatment market from 2025 to 2032, fueled by the rising adoption of minimally invasive surgeries. The availability of effective drugs and advanced treatment options in the region further supports this growth. In addition, the increasing focus on patient-centered care and enhanced healthcare access is expected to drive demand for innovative therapies in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Hemangiomas Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Hemangiomas Treatment Market Leaders Operating in the Market Are:

• Pierre Fabre Laboratories (France)
• BIOLASE, Inc. (U.S.)
• Bausch Health Companies Inc. (Canada)
• Cutera, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• IRIDEX Corporation (U.S.)
• Alma Lasers (Israel)
• LINLINE Medical Systems (Israel)
• Merck & Co., Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Akorn Operating Company LLC (U.S.)
• Pfizer Inc. (U.S.)

Latest Developments in Hemangiomas Treatment Market

• In March 2024, AstraZeneca's acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates, marks a significant step forward in cancer treatment. These advanced radioconjugates offer a targeted approach to therapy, potentially improving upon traditional methods such as chemotherapy and radiotherapy by enhancing effectiveness and reducing side effects. This strategic acquisition highlights AstraZeneca's commitment to revolutionizing oncology research and underscores its goal of reshaping cancer care with innovative therapeutic solutions
• In June 2023, Candela Corporation announced an expansion of its FDA-cleared Vbeam Family of Pulsed Dye Lasers (PDL) to include the 595 nm wavelength for treating pediatric patients with cutaneous capillary malformations, such as port wine stains (PWS), as well as infantile and congenital hemangiomas
• In July 2023, the American Society for Laser Medicine and Surgery (ASLMS) collaborated with the Vascular Birthmarks Foundation (VBF) and an international, multidisciplinary team to establish consensus guidelines for the use of laser therapy in treating vascular birthmarks
• In December 2021, research led by the Centenary Institute and Harvard Medical School revealed that a compound found in current beta-blocker treatments could be repurposed to enhance both the safety and effectiveness of therapies for infantile hemangiomas

SKU-50413